DC
LCTX icon

Diametric Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Diametric Capital’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.3K Buy
+59,029
New +$99.5K 0.02% 420
2023
Q2 		– Sell
-50,875
Closed -$76.3K – 412
2023
Q1 		$76.3K Buy
+50,875
New +$71K 0.04% 286
2021
Q2 		– Sell
-26,712
Closed -$63K – 166
2021
Q1 		$63K Buy
+26,712
New +$64.1K 0.05% 144
2020
Q3 		– Sell
-23,567
Closed -$21K – 152
2020
Q2 		$21K Buy
+23,567
New +$20.7K 0.02% 139

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $3.03B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return